Tetra Bio Pharma

Orléans-based medical cannabinoid company closed a similar $11.5M funding round a little less than two weeks ago.
East Ottawa firm says it intends to use the money to advance clinical testing on a cannabis-based pain-relief therapy for cancer patients.
The biopharmaceutical firm says it will use the funds to advance clinical testing for its PPP001 drug candidate, a potential pain-relieving therapy for late-stage cancer patients.
Former B.C. health minister joins Gatineau’s Hydropothecary as corporate social responsibility vice-president
Armed with a new name and fresh funding, a local medical marijuana firm says it hopes to bring its pharmaceutical product to market in early 2018, a company executive says.